Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to ...

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

Moderna stock jumped late Friday on reports the FDA's top vaccine official, Vinay Prasad, will step down amid mounting ...

The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.

Moderna (MRNA) stock rises as a $950M payment to resolve a patent dispute with Arbutus (ABUS) and Roivant (ROIV) lifts a key legal overhang. Read more here.

The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.